MedTrace Logo

Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

NCT07792408 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2026-08-28

No results posted yet for this study

Summary

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

DRUG

VX-407

Tablets for Oral Administration.

DRUG

LNG/EE

Combination Tablets for Oral Administration.

DRUG

NGM/EE

Combination Tablets for Oral Administration.

DRUG

NET/EE

Combination Tablets for Oral Administration.

DRUG

DRSP/EE

Combination Tablets for Oral Administration.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-28
Primary Completion
2027-03-11
Completion
2027-03-20
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07792408 on ClinicalTrials.gov